Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Stopped Despite the efforts of our dedicated team and initial progress, we were unable to secure the necessary financial resources to continue the study. We appreciate the support and participation of all involved.

Conditions

• Relapsed Chronic Lymphocytic Leukemia
• Refractory Chronic Lymphocytic Leukemia
• Diffuse Large B Cell Lymphoma
• Follicular Lymphoma
• Richter's Transformation

Interventions

• DRUG: DTRM-555

Sponsor

Zhejiang DTRM Biopharma